Our Supply Chain
1.End-to-End Supply Chain Transparency — From raw material sourcing to final delivery, full visibility at every stage
2.GMP-Compliant Manufacturing — ISO 9001:2015 certified facilities with ICH Q7 GMP standards
3.Global Cold-Chain Distribution — Temperature-controlled logistics spanning 50+ countries
4.Quality-First Procurement — Rigorous supplier audits, batch testing, and full traceability
Raw Material Sourcing
Zhaoke Bio maintains a robust global supply network spanning 15+ countries to ensure uninterrupted access to premium raw materials for peptide synthesis. Our procurement team vets every supplier against rigorous quality, ethical, and sustainability criteria — so you can trust the integrity of every peptide from the very first amino acid.
Strategic partnerships with certified raw material suppliers across North America, Europe, and Asia: (1) Amino acid suppliers: Bachem AG (Switzerland), Ajinomoto (Japan), Evonik (Germany), Hanwha (South Korea) — all with ISO 9001 and cGMP certification; (2) Reagent partners: Thermo Fisher, Sigma-Aldrich (Merck), TCI Chemicals for coupling reagents, resins, and protecting groups; (3) Dual-sourcing strategy: every critical raw material has at least two qualified suppliers to eliminate single-source risk; (4) Safety stock: 6-month buffer inventory for high-demand amino acids (Gly, Ala, Leu, Lys, Arg) and specialty reagents; (5) New supplier onboarding: 90-day qualification process including COA verification, sample testing, facility audit, and stability evaluation. Annual supplier performance review with scorecards covering quality (40%), delivery (30%), price (20%), and service (10%).
Multi-layer incoming quality control (IQC) ensures only certified raw materials enter production: (1) Certificate of Analysis (CoA) verification: every lot checked against pharmacopeial standards (USP/EP/ChP) for identity (IR/NMR), purity (HPLC ≥98%), moisture (KF ≤0.5%), and optical rotation; (2) In-house retesting: 100% of amino acid lots undergo independent HPLC purity analysis, optical rotation measurement, and TLC identity confirmation — rejects are quarantined and returned; (3) Impurity profiling: heavy metals (ICP-MS for Pb, As, Cd, Hg), residual solvents (GC-MS per ICH Q3C), and microbial testing (TAMC/TYMC/endotoxin); (4) Stability monitoring: accelerated stability testing (40°C/75% RH, 6 months) for all new raw materials before approval; (5) Lot tracking: barcode-based ERP system tracks every raw material lot from receipt through production to finished product — full forward and backward traceability. Rejection rate: <2% annually, well below industry average of 5-8%.
Intelligent inventory management powered by demand forecasting and safety stock protocols: (1) ABC classification: A-class amino acids (20 natural amino acids, high turnover) maintained at 6-month stock; B-class specialty amino acids (D-amino acids, N-methyl, beta-amino acids) at 3-month stock; C-class rare building blocks at 1-month stock with 2-week replenishment lead time; (2) Demand forecasting: AI-driven MRP system analyzes 24-month order history, seasonal trends, and market intelligence to predict material requirements 12 weeks in advance; (3) Temperature-controlled warehousing: amino acids stored at -20°C (long-term) and 2-8°C (working stock) with 24/7 monitoring and automated alert systems; (4) FIFO/FEFO rotation: first-in-first-out / first-expiry-first-out enforced by WMS to prevent material obsolescence; (5) Emergency procurement protocol: pre-negotiated expedited shipping agreements with key suppliers for critical material shortages — typical emergency delivery: 5-7 business days globally. Inventory turnover ratio: 8.5x annually (industry benchmark: 6x).
Comprehensive supplier qualification and ongoing audit program: (1) Initial qualification: on-site audits covering quality management (ISO 9001), manufacturing practices (ICH Q7), environmental compliance (ISO 14001), and occupational safety (ISO 45001); minimum audit score: 85/100 for approval; (2) Annual re-audits: scheduled on-site or remote audits with focus on CAPA (Corrective and Preventive Action) closure, change control documentation, and deviation trend analysis; (3) Ethical sourcing: all suppliers must sign Zhaoke’s Supplier Code of Conduct covering anti-corruption, labor rights (no child/forced labor), and environmental responsibility; (4) Conflict minerals: full disclosure and smelter verification for metals used in catalysts and equipment; (5) ESG scoring: quarterly ESG (Environmental, Social, Governance) assessment with targets for carbon footprint reduction, renewable energy usage, and diversity metrics. Supplier audit completion rate: 100% for A-class, 95% for B-class annually.
Manufacturing & Production
State-of-the-art facilities designed for peptide API production from milligram to multi-kilogram scale, with GMP compliance at every step.
Zhaoke Bio operates state-of-the-art manufacturing facilities designed for peptide API production from milligram to multi-kilogram scale. Our integrated approach combines solid-phase peptide synthesis (SPPS), liquid-phase synthesis, and hybrid methodologies — all within a controlled environment that meets or exceeds global GMP standards. Every production batch is monitored in real-time with automated process analytical technology (PAT) to ensure consistency, purity, and compliance.
Purpose-built manufacturing suites with dedicated areas for different synthesis scales and product types: (1) Research-scale lab: 4 fume hoods for method development, 2-50 mg scale, rapid turnaround for feasibility studies and analytical method validation; (2) Pilot plant: 6 SPPS reactors (50 mL to 5 L) with automated amino acid dispensing, temperature-controlled coupling (0-60°C), and real-time UV monitoring for deprotection completion; (3) Commercial production: 4 large-scale reactors (10-100 L) for bulk API manufacturing, with CIP/SIP systems and dedicated HVAC with HEPA H14 filtration; (4) Purification suite: preparative HPLC systems (Waters Prep 150, Agilent 1260 Infinity II) with column sizes from 50 mm to 150 mm ID, capable of processing 100g-5kg crude peptide per batch; (5) Lyophilization: 6 freeze-dryers (Labconco FreeZone series, 6L to 18L capacity) with programmable shelf temperature (-50°C to +40°C) and vacuum control for optimal cake formation. Facility classification: ISO 8 (Class 100,000) for synthesis, ISO 7 (Class 10,000) for purification and packaging. Annual production capacity: 500+ kg total peptide output.
Rigorous in-process controls (IPC) at every stage of manufacturing to catch deviations before they become defects: (1) Coupling efficiency monitoring: Kaiser ninhydrin test after every coupling cycle — target >99.5%; failed cycles trigger automatic double-coupling protocol; (2) HPLC purity checkpoints: analytical HPLC at 4 critical stages — crude cleavage, after first purification, after final purification, and after lyophilization; (3) Mass spectrometry identity: MALDI-TOF confirmation after synthesis completion and after final purification — MW tolerance ±0.1%; (4) In-process environmental monitoring: particle counts (ISO 14644), viable air sampling, surface swabs, and personnel monitoring every 4 hours during production; (5) Electronic batch records (EBR): 100% paperless manufacturing with real-time data capture from all equipment — any deviation triggers automatic supervisor notification and investigation workflow. In-process rejection rate: <3% (industry average: 8-12%).
Flexible manufacturing architecture designed to scale from R&D to commercial without technology transfer bottlenecks: (1) Linear scalability: validated scale-up factors from 50 mL (lab) → 500 mL (pilot) → 5 L (pilot) → 50 L (commercial) → 100 L (commercial) with documented equivalency studies; (2) Parallel processing: up to 12 SPPS syntheses can run simultaneously across research, pilot, and commercial suites — enabling concurrent multi-project execution; (3) Campaign manufacturing: dedicated production blocks for high-volume products (e.g., GLP-1 agonists, somatostatin analogs) with campaign sizes from 1 kg to 50 kg per batch; (4) Rapid scale-up: standard 4-week timeline from pilot to commercial production for established products; new products require 8-12 weeks for process validation and stability studies; (5) Capacity utilization: current utilization at 72% with 28% headroom reserved for emergency orders and new product introductions — planned capacity expansion of +40% by Q4 2026. Current monthly output: ~45 kg peptides across 120+ SKUs.
Unwavering commitment to batch-to-batch reproducibility with comprehensive documentation packages: (1) Process validation (PV): executed per ICH Q8/Q9/Q11 guidelines with Design of Experiments (DoE) — critical process parameters (CPPs) identified and controlled within proven acceptable ranges (PAR); (2) Batch release criteria: every batch must pass 13 QC parameters including HPLC purity (≥ target ± 1%), MS identity (±0.1%), peptide content (≥90%), moisture (≤5%), endotoxin (<10 EU/mg), and bioburden (<100 CFU/g); (3) Statistical process control (SPC): Cpk (process capability index) maintained >1.33 for all CPPs — real-time control charts with automated out-of-specification alerts; (4) Batch records: complete manufacturing history including raw material lots, equipment used, process parameters, IPC results, deviation reports, and QC release data — retained for product lifetime + 3 years; (5) Annual Product Quality Review (APQR): comprehensive analysis of all batches, complaints, deviations, and CAPAs with trend analysis and continuous improvement plans. Batch-to-batch RSD: <2% for purity, <3% for yield.
Logistics & Distribution
Purpose-built cold-chain infrastructure covering 50+ countries across 6 continents, maintaining product integrity from our door to yours.
Zhaoke Bio’s logistics infrastructure is purpose-built for temperature-sensitive biopharmaceutical products. Our global distribution network covers 50+ countries across 6 continents, with validated cold chain protocols that maintain product integrity from our door to yours — whether it’s a 10 mg research sample or a 100 kg commercial shipment.
End-to-end cold chain management with redundant temperature control at every touchpoint: (1) Storage infrastructure: -80°C ultra-low freezers (Thermo Scientific TSX60086D, 28.8 cu ft capacity), -20°C walk-in cold rooms (30 m²), and 2-8°C refrigerated facilities (50 m²) — all with 24/7 temperature monitoring and SMS/email alerts; (2) Phase-change materials: validated gel packs (2-8°C), dry ice (-78°C), and liquid nitrogen vapor shippers (-150°C) for ultra-stable peptides; (3) Insulated packaging: triple-wall vacuum-insulated containers with thermal barriers providing >96 hours of validated temperature maintenance for international shipments; (4) Real-time data loggers: Sensitech TempTale 4 and Temptime TransTracker monitors record temperature every 5 minutes with GPS location tracking — data uploaded to cloud dashboard accessible by clients; (5) Cold chain validation: annual thermal mapping studies per ISTA 7E standards for all shipping lanes, with documented temperature profiles for summer/winter extremes. Cold chain breach rate: <0.1% over 10,000+ shipments.
Strategically positioned distribution hubs for rapid delivery to major pharmaceutical markets: (1) Asia-Pacific hub (Shenzhen, China): primary distribution center with same-day dispatch for domestic orders, 2-day delivery to Japan/South Korea/Singapore, 3-day to Australia; (2) European hub (Rotterdam, Netherlands): bonded warehouse with EU REACH compliance, 2-day delivery to Germany/France/UK, 3-day to Scandinavia and Eastern Europe; (3) North American hub (San Diego, USA): FDA-registered facility with DEA-compliant storage, 2-day ground shipping to West Coast, 3-day to East Coast; (4) Regional partners: authorized distributors in India (Mumbai), Brazil (São Paulo), UAE (Dubai), and South Africa (Johannesburg) for local customs clearance and last-mile delivery; (5) Shipping carriers: primary contracts with DHL Express (global), FedEx International Priority, and UPS Worldwide Saver — negotiated rates with pre-clearance documentation to minimize customs delays. Average transit times: Asia-Pacific 2-3 days, Europe 3-5 days, North America 3-5 days, rest of world 5-8 days. Customs clearance success rate: 99.2%.
Complete shipment visibility from order confirmation to delivery with proactive exception management: (1) Client portal: secure online dashboard (supply.zhaokebio.com) showing order status, production progress, QC results, shipping label, tracking number, and estimated delivery date — updated every 2 hours; (2) Multi-carrier tracking: unified tracking interface integrating DHL, FedEx, UPS, and regional carriers with automatic carrier detection from tracking number; (3) Temperature monitoring: live temperature data from embedded data loggers visible on portal map with color-coded status (green = in range, yellow = approaching limit, red = excursion); (4) Automated notifications: email/SMS alerts at 6 milestones — order confirmed, production complete, QC passed, shipped, customs cleared, delivered; (5) Exception management: dedicated logistics team monitors all in-transit shipments — any delay, temperature excursion, or customs hold triggers immediate client notification with resolution plan. Average client inquiry resolution time: <2 hours. On-time delivery rate: 97.5% (target: 95%).
Supply Chain Compliance
Our compliance framework ensures every product, document, and process meets the requirements of FDA, EMA, NMPA, and other major regulatory bodies.
Regulatory compliance is the foundation of our supply chain operations. Zhaoke Bio maintains certifications and quality agreements that satisfy the most stringent international standards — from API manufacturing to controlled substance handling.
Comprehensive regulatory framework covering manufacturing, export, and quality standards: (1) Manufacturing certifications: ISO 9001:2015 (Quality Management System — certified by SGS, certificate CN21/30158), ISO 14001:2015 (Environmental Management), ISO 45001:2018 (Occupational Health & Safety); (2) GMP compliance: ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients — validated manufacturing processes, qualified equipment, trained personnel, and documented standard operating procedures (SOPs); (3) Export compliance: registered with China Ministry of Commerce (MOFCOM) for peptide API export, DEA registration for controlled substance precursors, BIS (Bureau of Industry and Security) classification for dual-use items; (4) Import market registrations: US FDA Establishment Registration (FEI pending), EU REACH registration (pre-registered for amino acid derivatives), Health Canada DINS, TGA (Australia) ARTG listing support; (5) Pharmacopeial compliance: all products manufactured to USP, EP, BP, or ChP specifications with certified reference standards; full ICH Q3C residual solvent and ICH Q3D elemental impurity assessment available. Last regulatory inspection: NMPA GMP inspection (December 2024) — zero critical findings, 2 minor observations closed within 30 days.
Unbroken traceability from raw material to finished product delivery with blockchain-enabled documentation: (1) Raw material traceability: every amino acid lot traced back to manufacturer batch number, CoA, and supplier audit report — 2-year forward and 10-year backward retention; (2) Manufacturing traceability: electronic batch records (EBR) capture every operation — equipment ID, operator, timestamp, process parameter, IPC result, and any deviation with investigation report; (3) Quality traceability: QC sample retention for 3 years post-expiry, stability study samples stored at ICH Q1A conditions with annual testing, out-of-specification (OOS) investigations completed within 30 days; (4) Distribution traceability: serialization at unit level (vial/bottle) with 2D Data Matrix codes containing batch number, manufacturing date, expiry date, and storage conditions — scanned at every transfer point; (5) Chain of custody: tamper-evident seals on all shipments, documented handoff at every logistics node (warehouse → carrier → customs → local distributor → client), with signature capture at delivery. Blockchain ledger: immutable record stored on Hyperledger Fabric with client-accessible verification portal. Audit trail availability: 100% within 4 hours of request.